Dyne’s $305M offering; Nanobiotix delays Ph2 readout

Dyne Ther­a­peu­tics ex­pects to net $305M in stock sale: The com­pa­ny on Mon­day dropped up­dat­ed stock-mov­ing re­sults for its my­oton­ic dy­s­tro­phy type 1 and Duchenne mus­cu­lar dy­s­tro­phy ther­a­pies. With the pro­ceeds, Dyne ex­pects it can fund op­er­a­tions in­to the sec­ond half of 2026, ac­cord­ing to an SEC fil­ing. — Lei Lei Wu

Nanobi­otix push­es back read­out for head and neck can­cer drug: The biotech now plans to present in­ter­im Phase 3 da­ta for its John­son & John­son-part­nered ra­dioen­hancer in the first half of 2026. It had orig­i­nal­ly planned to share da­ta in mid-2025. The de­lay comes as the com­pa­nies laid out plans to for­go a fu­til­i­ty analy­sis and con­duct an in­tern analy­sis on­ly af­ter the fi­nal pa­tient is re­cruit­ed. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.